Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeEXECUTIVESDr. Woodrow Myers Joins the Freespira Board of Directors

Dr. Woodrow Myers Joins the Freespira Board of Directors

Freespira, Inc., maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, today announced that Woodrow (Woody) Myers, MD, has joined the company’s Board of Directors.

Dr. Woodrow Myers is a nationally recognized leader in the development of healthcare quality initiatives and advanced healthcare management programs. He has over 40 years’ experience as a physician and clinical and business leader at some of the industry’s largest and most prestigious healthcare enterprises. In his current role, as managing director of Myers Ventures LLC, he has served as chief medical officer and chief healthcare strategist for Blue Cross Blue Shield of Arizona, CEO for Valitàs Health Services (Corizon Health), and a consultant to the $3 billion California Endowment, that state’s largest private health foundation.

“Freespira’s breakthrough treatment for panic disorder and PTSD epitomizes the critical importance of innovation in healthcare – and the power of human-centered  technology to make a difference in the lives of those who struggle with debilitating mental illnesses on a daily basis,” said Dr. Myers. “I’m excited to join Freespira’s Board of Directors to help the company continue to expand its already strong reach. Together, we can serve more of the millions of Americans who are suffering and desperately need access to new life-changing therapies.”

Freespira CEO Dean Sawyer commented, “We’re honored that Dr. Myers is joining our Board of Directors. Throughout his impressive career, he has proven to be deeply committed to improving healthcare by embracing innovation and technology, especially to support our nation’s underserved populations who deserve far better access to far better care. Most importantly, Dr. Myers brings not only invaluable knowledge and experience to the Board but also a strong passion for our mission of helping people to lead happier, healthier, symptom-free lives.”

Dr. Myers previously served as the executive vice president and chief medical officer of WellPoint, Inc., where he established the Healthcare Quality Assurance Division. Prior to that, he served as the director of healthcare management at the Ford Motor Company where he initiated quality assurance metrics for Ford healthcare vendors and established new global health and safety policies. Prior to Ford, he was corporate medical director for The Associated Group (now Anthem Blue Cross Blue Shield). He is also a former health commissioner for New York City and the state of Indiana.

He earned his medical degree (MD) from Harvard University, and a Master of Business Administration (MBA) from Stanford University. Early in his medical career he worked as an emergency room physician and as a critical care intensivist and in both roles as a clinical teacher.

The Freespira Board of Directors now includes the following members in addition to Dr. Myers and Mr. Sawyer: Executive chairman Russ Siegelman, a former Kleiner Perkins leader and current Stanford Business School lecturer; Ned Scheetz, founder and managing partner of Aphelion Capital; Jonathan MacQuitty, venture partner at Lightspeed Venture Partners; Steve Schwartz, executive vice president of mergers and acquisitions for Senior Connect Acquisition Corp.; and Debra Reisenthel, founding CEO of Freespira.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

ProSomnus® Sleep Technologies Adds John E. Remmers, MD, to Leadership Team

Dr. John E. Remmers will provide expert medical and strategic guidance on a range of initiatives, including research and development, regulatory clearances, company strategy, medical education, and clinical investigations.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.

Christopher Joyce Joins Miach Orthopaedics as VP & CFO

Christopher Joyce has joined as vice president and chief financial officer, and Kevin Sidow has been appointed to the company’s board of directors.

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion.

Recombinant Technologies is Raising Capital to Roll Out a Game Changing Alzheimer’s Treatment

Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted.

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

By using this website you agree to accept Medical Device News Magazine Privacy Policy